The Priority Review

Tag

DBV712

1 story

  1. Clinical trials

    DBV Technologies posts results of Phase 3 DBV712 study in peanut-allergic children

    The study, completed with 304 participants, posted results on ClinicalTrials.gov on October 28, 2026. It was an open-label extension of the EPITOPE study evaluating long-term clinical benefit and safety of DBV712 in peanut-allergic children.